tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Sol-Gel Technologies Reports Strong Q2 2025 Financials and Strategic Developments

Story Highlights
  • Sol-Gel Technologies reported Q2 2025 revenue of $17.2 million, boosted by a $16 million deal with Mayne Pharma.
  • The company completed Phase-3 trial enrollment for SGT-610 and advances SGT-210 trials despite challenges.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sol-Gel Technologies Reports Strong Q2 2025 Financials and Strategic Developments

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Sol-Gel Technologies ( (SLGL) ) is now available.

On August 15, 2025, Sol-Gel Technologies announced its financial results for Q2 2025, highlighting a significant increase in revenue to $17.2 million compared to $5.4 million in the same period of 2024, primarily due to a $16 million agreement with Mayne Pharma. The company has completed patient enrollment for its Phase-3 trial of SGT-610, with results expected in Q4 2026, and is advancing its Phase-1b trial of SGT-210 despite recruitment challenges. The strategic sale of U.S. rights to EPSOLAY and TWYNEO aims to extend Sol-Gel’s cash runway into 2027, supporting further R&D investments and potential market expansion.

The most recent analyst rating on (SLGL) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Sol-Gel Technologies stock, see the SLGL Stock Forecast page.

Spark’s Take on SLGL Stock

According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.

Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.

To see Spark’s full report on SLGL stock, click here.

More about Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a dermatology company based in Ness Ziona, Israel, specializing in pioneering treatments for severe skin conditions. The company is engaged in advanced clinical trials for products like SGT-610 for Gorlin syndrome and SGT-210 for Darier disease. Sol-Gel also has two approved dermatology products, TWYNEO and EPSOLAY, focusing on acne and rosacea treatments respectively.

Average Trading Volume: 18,386

Technical Sentiment Signal: Buy

Current Market Cap: $42.48M

Find detailed analytics on SLGL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1